Plus Therapeutics' subsidiary CNSide Diagnostics has signed a regional agreement with Medical Mutual to provide the CNSide® Cerebrospinal Fluid Tumor Cell Enumeration assay to about 1.2 million people in Ohio and Kentucky. This expands the total coverage of the CNSide CSF assay to approximately 127 million people nationwide. The assay aids in rapid diagnosis and treatment monitoring for patients with leptomeningeal metastases, showing high accuracy and influencing treatment decisions in 90% of cases. Plus Therapeutics plans to rebrand as Cerenome, Inc. in August 2026, continuing to develop integrated CNS cancer diagnostics and therapeutics.
Evercore ISI raised Ross Stores' price target to $276, suggesting a 12.5% upside from its current $245.36 price. The boost reflects strong expectations for Q2, with projected revenues of $6.10 billion (up 10.7%) and earnings per share of $1.92 (up 23...
Fabrinet is set to report strong Q3 2026 earnings with revenue forecasted at about $1.276 billion, a 41% increase year-over-year, driven by demand in Telecom and Data Center sectors. Earnings per share are expected to rise 45% to $3.81, reflecting ro...
Jernigan Capital, a REIT specializing in financing self-storage facilities, saw its stock rise over 11% to $24.00, reaching a new 52-week high. Analysts have a consensus "Moderate Buy" rating with an average 12-month price target of $27.50, suggestin...
CrowdStrike, a leading cybersecurity firm, has seen its stock price increase by 85% year-to-date, reaching a market cap over $220 billion. Investment firm Cowen & Co. reiterated a "Buy" rating and raised the price target to $235, citing strong financ...
Synchrony has announced a collaboration with OpenAI to enhance AI-driven shopping and payment experiences by integrating financing, rewards, and loyalty into AI-native platforms. This partnership includes launching a ChatGPT plugin that allows consum...
